Rigel Pharmaceuticals Inc (RIGL)
1.20
+0.05
(+4.35%)
USD |
NASDAQ |
May 03, 16:00
1.19
-0.01
(-0.83%)
After-Hours: 20:00
Rigel Pharmaceuticals Net Income (Quarterly): 0.737M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.737M |
| September 30, 2023 | -5.692M |
| June 30, 2023 | -6.60M |
| March 31, 2023 | -13.54M |
| December 31, 2022 | 1.401M |
| September 30, 2022 | -19.04M |
| June 30, 2022 | -13.49M |
| March 31, 2022 | -27.44M |
| December 31, 2021 | -22.64M |
| September 30, 2021 | -20.95M |
| June 30, 2021 | -13.82M |
| March 31, 2021 | 39.50M |
| December 31, 2020 | -19.24M |
| September 30, 2020 | -14.17M |
| June 30, 2020 | -17.58M |
| March 31, 2020 | 21.24M |
| December 31, 2019 | -17.20M |
| September 30, 2019 | -11.49M |
| June 30, 2019 | -20.61M |
| March 31, 2019 | -17.60M |
| December 31, 2018 | 3.228M |
| September 30, 2018 | -23.77M |
| June 30, 2018 | -25.56M |
| March 31, 2018 | -24.38M |
| December 31, 2017 | -25.87M |
| Date | Value |
|---|---|
| September 30, 2017 | -17.66M |
| June 30, 2017 | -19.15M |
| March 31, 2017 | -15.31M |
| December 31, 2016 | -15.59M |
| September 30, 2016 | -22.63M |
| June 30, 2016 | -13.53M |
| March 31, 2016 | -17.46M |
| December 31, 2015 | -12.69M |
| September 30, 2015 | -6.672M |
| June 30, 2015 | -13.91M |
| March 31, 2015 | -18.19M |
| December 31, 2014 | -22.27M |
| September 30, 2014 | -20.94M |
| June 30, 2014 | -25.39M |
| March 31, 2014 | -22.30M |
| December 31, 2013 | -16.86M |
| September 30, 2013 | -23.82M |
| June 30, 2013 | -22.77M |
| March 31, 2013 | -25.57M |
| December 31, 2012 | -25.47M |
| September 30, 2012 | -25.46M |
| June 30, 2012 | -24.74M |
| March 31, 2012 | -23.17M |
| December 31, 2011 | -25.79M |
| September 30, 2011 | -17.93M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-27.44M
Minimum
Mar 2022
39.50M
Maximum
Mar 2021
-9.506M
Average
-13.82M
Median
Jun 2021
Net Income (Quarterly) Benchmarks
| Nektar Therapeutics | -42.08M |
| Avid Bioservices Inc | -6.006M |
| Stereotaxis Inc | -5.04M |
| Cara Therapeutics Inc | -32.34M |
| Ardelyx Inc | -28.80M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 35.79M |
| Total Expenses (Quarterly) | 33.83M |
| EPS Diluted (Quarterly) | 0.01 |
| Enterprise Value | 213.12M |
| Gross Profit Margin (Quarterly) | 89.41% |
| Profit Margin (Quarterly) | 2.06% |
| Earnings Yield | -11.67% |
| Normalized Earnings Yield | -11.67 |